Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 78

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 78
---
 or potential material conflicts of interest between or among (i) the Sponsor and its affiliates, the NorthView Initial Stockholders, NorthView’s officers or directors, NorthView’s promotors, Profusa’s officers or directors, and (ii) the unaffiliated security holders of NorthView. In addition, I -Bankersand Dawson James, NorthView’s advisors and the managing underwriters of NorthView’s IPO, have a financial interest that may conflict with your interests. These interests may have influenced NorthView’s directors in approving the Business Combination and making their recommendation to vote in favor of the approval of the Business Combination Proposal and the other proposals described in this proxy statement/prospectus. For a further discussion of these considerations, see the section entitled “Proposal 1 — The Business Combination Proposal — Interests of Certain Persons in the Business Combination and Conflicts of Interest”. Risk Factors This proxy statement/prospectus provides you with detailed information about the Business Combination and related transactions. You are encouraged to carefully read the entire document and the documents incorporated by reference. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER “RISK FACTORS” BEGINNING ON PAGE 27. Some of the risks related to Profusa, NorthView, and New Profusa are summarized below: Risks Related to Profusa •Profusa and its auditors have substantial doubt about Profusa’s ability to continue as a going concern, which may hinder Profusa’s ability to obtain further financing. •Profusa has a limited operating history on which to assess the prospects for its business and it has incurred losses since inception. Profusa anticipates that it will continue to incur significant losses for at least the next several years as it continues to commercialize its existing products and services and seeks to develop and commercialize new products and services. •The clinical trial process is lengthy and expensive with uncertain outcomes. Results of earlier studies may not be predictive of future clinical trial results, or the safety or efficacy profile for such products. •Profusa’s success depends upon market acceptance of its products and services, its ability to develop and commercialize existing and new products and services and generate revenues, and its ability to identify new markets for its technology. •Profusa has limited experience in marketing and selling its products and related services, and if Profusa is unable to successfully commercialize its products and related services, its business and operating results will be adversely affected. •Medical device development is costly, and Profusa’s research and development efforts that it undertakes